Trials & R&D · first seen yesterday, updated yesterday

Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren's study

1 outlet Amgen FDA

Amgen is awaiting another Phase 3 readout for the investigational Sjögren's disease therapy, set for later this year. William Blair anticipates that at least two trials will be needed to support an FDA application.

Summary from BioSpace - All News.

Coverage 1 article · 1 outlet

BioSpace - All News yesterday
Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren's study